Daphnicalycinones A and B, Daphniphyllum alkaloids from the roots of Daphniphyllum calycinum with anti-inflammatory activity

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-03-18 DOI:10.1016/j.phytol.2025.102946

Jiaqi Guo , Wenlong Li , Runchao Ma , Lizhu Han , Jiani Ying , Xiongyu Meng , Huaqiang Li , Qi Shi , Luping Qin

引用次数: 0

Abstract

Two undescribed Daphniphyllum alkaloids, daphnicalycinones A and B (1 and 2), together with three known analogues, daphnezomine D (3), calycindaphine H (4) and calycindaphine A (5) were isolated from the roots of Daphniphyllum calycinum. Their planar structures and stereo-structures were determined by extensively spectral analyses, including HRESIMS, NMR, DP4 + computational method and single-crystal X-ray crystallography. The anti-inflammatory activities of compounds 1−5 were tested on LPS-induced RAW 264.7 cells, and the results showed that 2 and 5 exhibited potent inhibitory effects with the IC₅₀ values of 1.53 ± 0.35 μM and 10.13 ± 0.72 μM, respectively.

查看原文本刊更多论文

从水蚤根部提取的水蚤碱类生物碱A和B具有抗炎活性

从水蛭根中分离得到了两种水蛭生物碱，水蛭碱酮A和水蛭碱酮B(1和2)，以及三种已知的类似物水蛭碱D(3)、水蛭碱H(4)和水蛭碱A(5)。通过广泛的光谱分析，包括hresms， NMR， DP4 + 计算方法和单晶x射线晶体学，确定了它们的平面结构和立体结构。结果表明，化合物1 ~ 5对lps诱导的RAW 264.7细胞具有较强的抑制作用，IC50值分别为1.53 ± 0.35 μM和10.13 ± 0.72 μM。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.